헬리코박터 파일로리 진단 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Helicobacter Pylori Diagnostics Market size is expected to reach USD 1302.30 Million in 2034 from USD 762.37 Million (2025) growing at a CAGR of 6.13% during 2026-2034.

The Global Helicobacter Pylori Diagnostics Market is witnessing steady growth due to the rising prevalence of gastric infections, ulcers, and stomach cancer worldwide. Increasing awareness about early diagnosis and preventive healthcare is encouraging more people to undergo testing. The growing availability of non-invasive diagnostic methods, such as breath tests and stool antigen tests, has further supported market expansion. In addition, improved healthcare infrastructure in emerging economies is boosting access to advanced diagnostic services.

Key growth drivers include technological advancements in diagnostic kits, rising healthcare spending, and supportive government screening programs. The demand for accurate and rapid diagnostic solutions is increasing among hospitals and diagnostic laboratories. Lifestyle changes, poor dietary habits, and increasing cases of gastrointestinal disorders are also contributing to higher testing volumes. Moreover, the integration of molecular diagnostic techniques is enhancing detection accuracy and driving adoption.

Looking ahead, the market is expected to grow consistently with continuous innovation in point-of-care testing and personalized medicine approaches. Expanding healthcare coverage and increasing focus on preventive care will create new opportunities. Emerging markets in Asia-Pacific and Latin America are likely to witness strong demand due to improving awareness and medical facilities. Overall, the future outlook remains positive as early detection becomes a priority in global healthcare strategies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Instruments
• Reagents
• Services

By Technology

• Immunoassays
• POC
• Molecular Diagnostics

By End-user

• Hospitals
• Diagnostics Laboratories
• Clinics

COMPANIES PROFILED

• Thermo Fisher Scientific, Biohit Oyj, Quest Diagnostics Incorporated, Meridian Bioscience, BioRad Laboratories, Alpha Laboratories Ltd, F HoffmannLa Roche Ltd, Coris BioConcept, Certest Biotec, Epitope Diagnostics Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Reagents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Technology
• 5.2. Immunoassays Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Molecular Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostics Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HELICOBACTER PYLORI DIAGNOSTICS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Technology
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Technology
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Technology
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Technology
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Technology
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL HELICOBACTER PYLORI DIAGNOSTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Thermo Fisher Scientific
  • 9.2.2 Biohit Oyj
  • 9.2.3 Quest Diagnostics Incorporated
  • 9.2.4 Meridian Bioscience
  • 9.2.5 Bio-Rad Laboratories
  • 9.2.6 Alpha Laboratories Ltd
  • 9.2.7 F. Hoffmann-La Roche Ltd
  • 9.2.8 Coris BioConcept
  • 9.2.9 Certest Biotec
  • 9.2.10 Epitope Diagnostics Inc